Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality.
cardiovascular disease
cardiovascular mortality
diabetes
glomerular hyperfiltration
renal hyperfiltration
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
16
05
2019
revised:
30
06
2019
accepted:
08
07
2019
pubmed:
13
7
2019
medline:
29
9
2020
entrez:
13
7
2019
Statut:
ppublish
Résumé
Renal hyperfiltration, defined as an increased glomerular filtration rate above normal values, is associated with early phases of kidney disease in the setting of various conditions such as obesity and diabetes. Although it is recognized that glomerular hyperfiltration, that is, increased filtration per nephron unit (usually studied at low glomerular filtration levels and often referred to as single nephron hyperfiltration), is a risk factor for the progression of chronic kidney disease, the implications of having renal hyperfiltration for cardiovascular disease and mortality risk are incompletely understood. Recent evidence from diverse populations, including healthy individuals and patients with diabetes or established cardiovascular disease, suggests that renal hyperfiltration is associated with a higher risk of cardiovascular disease and all-cause mortality. In this review, we critically summarize the existing studies, discuss possible mechanisms, and describe the remaining gaps in our knowledge regarding the association of renal hyperfiltration with cardiovascular disease and mortality risk.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2368-2383Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095-2128.
Melsom T, Mathisen UD, Ingebretsen OC, et al. Impaired fasting glucose is associated with renal hyperfiltration in the general population. Diabetes Care. 2011;34:1546-1551.
Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308:2349-2360.
Nitsch D, Grams M, Sang Y, et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ. 2013;346:f324.
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339-352.
Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073-2081.
Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. JASN. 2007;18:1307-1315.
Ruilope LM, Robles RG, Miranda B, et al. Renal effects of fenoldopam in refractory hypertension. J Hypertens. 1988;6:665-669.
Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the atherosclerosis risk in communities (ARIC) study. JASN. 2007;18:629-636.
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol. 2012;8:293-300.
Brenner BM, Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. Kidney Int. 1997;63:S124-S127.
Sasson AN, Cherney DZ. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes. 2012;3:1-6.
Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010;53:2093-2104.
Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia. 2009;52:691-697.
Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061-2068.
Wuerzner G, Pruijm M, Maillard M, et al. Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population. Am J Kidney Dis. 2010;56:303-312.
Stefansson VT, Schei J, Jenssen TG, Melsom T, Eriksen BO. Central obesity associates with renal hyperfiltration in the non-diabetic general population: a cross-sectional study. BMC Nephrol. 2016;17:172.
Dengel DR, Goldberg AP, Mayuga RS, Kairis GM, Weir MR. Insulin resistance, elevated glomerular filtration fraction, and renal injury. Hypertension. 1996;28:127-132.
Knight SF, Imig JD. Obesity, insulin resistance, and renal function. Microcirculation. 2007;14:349-362.
Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(suppl 2):64-78.
Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 1996;49:1774-1777.
Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925-1930.
Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A. 1985;82:5963-5967.
Eriksen BO, Lochen ML, Arntzen KA, et al. Subclinical cardiovascular disease is associated with a high glomerular filtration rate in the nondiabetic general population. Kidney Int. 2014;86:146-153.
van der Sande NG, Blankestijn PJ, Leiner T, et al. High ratios of kidney function to kidney size are related to mortality and kidney function decline in high-risk patients. Eur J Prev Cardiol. 2017;24:926-933.
Altay S, Onat A, Ozpamuk-Karadeniz F, Karadeniz Y, Kemaloglu-Oz T, Can G. Renal "hyperfiltrators" are at elevated risk of death and chronic diseases. BMC Nephrol. 2014;15:160.
Choi HM, Hyun YY, Lee KB, Kim H. High estimated glomerular filtration rate is associated with coronary artery calcification in middle-aged Korean men without chronic kidney disease. Nephrol Dial Transplant. 2015;30:996-1001.
Schmieder RE, Messerli FH, Garavaglia G, Nunez B. Glomerular hyperfiltration indicates early target organ damage in essential hypertension. JAMA. 1990;264:2775-2780.
Matsushita KMB, Woodward M, Emberson JR, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;18:1941-1951.
Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380:1649-1661.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605.
Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58:1651-1658.
Davis TM, Chubb SA, Davis WA. The relationship between estimated glomerular filtration rate trajectory and all-cause mortality in type 2 diabetes: the Fremantle diabetes study. Eur J Endocrinol. 2016;175:273-285.
Luo Y, Wang X, Wang Y, et al. Association of glomerular filtration rate with outcomes of acute stroke in type 2 diabetic patients: results from the China National Stroke Registry. Diabetes Care. 2014;37:173-179.
Inrig JK, Gillespie BS, Patel UD, et al. Risk for cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater-than-normal estimated glomerular filtration rate. CJASN. 2007;2:1215-1222.
Putaala J, Haapaniemi E, Gordin D, et al. Factors associated with impaired kidney function and its impact on long-term outcome in young ischemic stroke. Stroke. 2011;42:2459-2464.
Mostofsky E, Wellenius GA, Noheria A, et al. Renal function predicts survival in patients with acute ischemic stroke. Cerebrovasc Dis. 2009;28:88-94.
Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J. 2007;28:478-483.
Donfrancesco C, Palleschi S, Palmieri L, et al. Estimated glomerular filtration rate, all-cause mortality and cardiovascular diseases incidence in a low risk population: the MATISS study. PLoS ONE. 2013;8:e78475.
Reboldi G, Verdecchia P, Fiorucci G, et al. Glomerular hyperfiltration is a predictor of adverse cardiovascular outcomes. Kidney Int. 2018;93:195-203.
Yoo KD, Yoon HJ, Hwang SS, et al. Different association between renal hyperfiltration and mortality by sex. Nephrol Ther. 2017;22:804-810.
Tonelli M, Klarenbach SW, Lloyd AM, et al. Higher estimated glomerular filtration rates may be associated with increased risk of adverse outcomes, especially with concomitant proteinuria. Kidney Int. 2011;80:1306-1314.
Park M, Yoon E, Lim YH, Kim H, Choi J, Yoon HJ. Renal hyperfiltration as a novel marker of all-cause mortality. JASN. 2015;26:1426-1433.
Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ. 2010;341:c4986.
Cox HJ, Bhandari S, Rigby AS, Kilpatrick ES. Mortality at low and high estimated glomerular filtration rate values: a 'U' shaped curve. Nephron Clin Pract. 2008;110:c67-c72.
Sochett EB, Cherney DZ, Curtis JR, Dekker MG, Scholey JW, Miller JA. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. JASN. 2006;17:1703-1709.
Schmieder RE, Veelken R, Schobel H, Dominiak P, Mann JF, Luft FC. Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension. JASN. 1997;8:893-900.
Ruster C, Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin Nephrol. 2013;33:44-53.
Bemelmans RH, van der Graaf Y, Nathoe HM, et al. The risk of resting heart rate on vascular events and mortality in vascular patients. Int J Cardiol. 2013;168:1410-1415.
Cherney DZ, Sochett EB, Lai V, et al. Renal hyperfiltration and arterial stiffness in humans with uncomplicated type 1 diabetes. Diabetes Care. 2010;33:2068-2070.
Cherney DZ, Sochett EB. Evolution of renal hyperfiltration and arterial stiffness from adolescence into early adulthood in type 1 diabetes. Diabetes Care. 2011;34:1821-1826.
Cherney DZ, Reich HN, Jiang S, et al. Hyperfiltration and the effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol. 2012;303:R710-R718.
Yang GK, Maahs DM, Perkins B, Cherney DZI. Renal hyperfiltration and systemic blood pressure in patients with uncomplicated type 1 diabetes mellitus. PLoS ONE. 2013;8:e68908.
Lovshin JA, Skrtic M, Bjornstad P, et al. Hyperfiltration, urinary albumin excretion, and ambulatory blood pressure in adolescents with type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2018;314:F667-F674.
Bank N. Mechanisms of diabetic hyperfiltration. Kidney Int. 1991;40:792-807.
Bosma RJ, van der Heide JJ, Oosterop EJ, de Jong PE, Navis G. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int. 2004;65:259-265.
Shastri S, Sarnak MJ. Chronic kidney disease: high eGFR and mortality: high true GFR or a marker of frailty? Nat Rev Nephrol. 2011;7:680-682.
Oterdoom LH, Gansevoort RT, Schouten JP, de Jong PE, Gans ROB, Bakker SJL. Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population. Atherosclerosis. 2009;207:534-540.
Tomaszewski M, Charchar FJ, Maric C, et al. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int. 2007;71:816-821.
Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. JASN. 2005;16:3728-3735.
Har R, Scholey JW, Daneman D, et al. The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Diabetologia. 2013;56:1166-1173.
Har RL, Reich HN, Scholey JW, et al. The urinary cytokine/chemokine signature of renal hyperfiltration in adolescents with type 1 diabetes. PLoS ONE. 2014;9:e111131.
Cherney DZ, Konvalinka A, Zinman B, et al. Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. Diabetes Care. 2009;32:91-93.
Onat A, Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des. 2014;20:575-584.
Onat A, Can G, Murat S, Cicek G, Ornek E, Yuksel H. Aggregation of lipoprotein(a) to apolipoprotein A-I underlying HDL dysfunction as a major coronary risk factor. Anadolu Kardiyol Derg. 2013;13:543-551.
de Albuquerque RN, Neeland IJ, McCullough PA, Toto RD, McGuire DK. Effects of sodium glucose co-transporter 2 inhibitors on the kidney. Diab Vasc Dis Res. 2018;15:375-386.
Fernandez-Fernandez B, Izquierdo MC, Valino-Rivas L, et al. Albumin downregulates klotho in tubular cells. Nephrol Dial Transplant. 2018;33:1712-1722.
Izquierdo MC, Perez-Gomez MV, Sanchez-Nino MD, et al. Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant. 2012;27(suppl 4):iv6-iv10.
Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12:711-712.
Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ. 2007;176:S1-S44.
Hayashi A, Santo Y, Satomura K. Proteinuria and glomerular hypertrophy in extremely low-birthweight children. Pediatr Int. 2014;56:860-864.
Chaturvedi S, Ng KH, Mammen C. The path to chronic kidney disease following acute kidney injury: a neonatal perspective. Pediatr Nephrol. 2017;32:227-241.
Oliver-Williams C, Vladutiu CJ, Loehr LR, Rosamond WD, Stuebe AM. The association between parity and subsequent cardiovascular disease in women: the atherosclerosis risk in communities study. J Womens Health. 2019;28:721-727.
Piccoli GB, Attini R, Vigotti FN, et al. Is renal hyperfiltration protective in chronic kidney disease-stage 1 pregnancies? A step forward unravelling the mystery of the effect of stage 1 chronic kidney disease on pregnancy outcomes. Nephrol Ther. 2015;20:201-208.
Cachat F, Combescure C, Cauderay M, Girardin E, Chehade H. A systematic review of glomerular hyperfiltration assessment and definition in the medical literature. CJASN. 2015;10:382-389.
Afsar B, Elsurer R, Kirkpantur A, Kanbay M. Urinary sodium excretion and ambulatory blood pressure findings in patients with hypertension. J Clin Hypertens. 2015;17:200-206.
Santos EMD, Brito DJA, Franca A, Lages JS, Santos AMD, Salgado FN. Association between estimated glomerular filtration rate and sodium excretion in urine of African descendants in Brazil: a population-based study. J Bras Nefrol. 2018;40:248-255.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306.